Endocannabinoids - The new option in the treatment of metabolic syndrome and in smoking cessation;Endokanabinoidy - Nová možnost v léčbě metabolického syndromu a odvykání kouření

Casopis Lekaru Ceskych

Volumn 144, Issue 2, 2005, Pages 81-85

  Kvasnička, Tomáš ^a   Zima, Tomáš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Anamdamid; Endocannabinoids; Metabolic syndrome; Receptor CB1

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; RIMONABANT; AMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADIPOSE TISSUE; BODY WEIGHT; CARDIOVASCULAR DISEASE; ENVIRONMENTAL FACTOR; GENE INTERACTION; GLUCOSE METABOLISM; LIPID METABOLISM; METABOLIC SYNDROME X; REVIEW; RISK FACTOR; SMOKING CESSATION; WEIGHT REDUCTION; DRUG ANTAGONISM; HUMAN; METABOLISM; SMOKING;

ARACHIDONIC ACIDS; ENDOCANNABINOIDS; HUMANS; METABOLIC SYNDROME X; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RECEPTORS, CANNABINOID; SMOKING; SMOKING CESSATION; WEIGHT LOSS;

EID: 14644408836     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Reaven, P.: Metabolic syndrome. J. Insur. Med., 2004, 36, s. 132-142.
2. Haffner, S., Taegmeyer, H.: Epidemic obesity and metabolic syndrome. Circulation, 2003, 108, s. 1541-1545.
3. Reilly, M. P., rader, D. J.: The matabolic syndrome: more than the sum of its parts? Circulation, 2003, 108, s. 1546-1551.
4. Garber, A. J.: The metabolic syndrome. Med. Clin. North. Am., 2004, 88, s. 837-846.
5. Fong, T. M.: Targeting metabolic syndrome. Expert Opin Investig Drugs., 2004, 13, s. 1203-1206.
6. Balkau, B.: Smoking, type 2 diabetes and metabolic syndrome. Diabetes Metab., 2004, 30, s. 110-111.
7. Wingerchuk, D.: Cannabis for medical purposes: cultivating science, weeding out the fiction. Lancet, 2004, 364, s. 315-316.
8. Palmer, T.: Evidence in cannabis research. Br. J. Psychiatry, 2004, 184, s. 542-543.
9. Fride, E., Shohami, E.: The endocannabinoid system: function in survival of the embryo, the newborn and the neuron. Neuroreport, 2002, 13, s. 1833-1841.
10. Venance, L., Maldonado, R., Manzoni, O.: [Endocannabinoids in the central nervous system] Med. Sci (Paris), 2004, 20, s. 45-53.
11. Onaivi, E. S., Leonard, C. M., Ishiguro, H. et al.: Endocannabinoids and cannabinoid receptor genetics. Prog. Neurobiol., 2002, 66, s. 307-344.
12. Pertwee, R. G.: Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther., 1997, 74, s. 129-180.
13. Sim-Selley, L. J.: Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit. Rev. Neurobiol., 2003, 15, s. 91-119.
14. Mato, S., Del Olmo, E., Pazos, A.: Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur. J. Neurosci., 2003, 15, s. 88-92.
15. Contassot, E., Tenan, M., Schnuriger, V. et al.: Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol. Oncol., 2004, 93, s. 182-188.
16. Palmer, S. L., Khanolkar, A. D.: Makriyannis A. Natural and synthetic endocannabinoids and their structure-activity relationships. Curr. Pharm. Des., 2000, 6, s. 1381-1397.
17. Grotenhermen, F.: Pharmacology of cannabinoids. Neuro Endocrinol. Lett., 2004, 25, s. 14-23.
18. Piomelli, D., Beltramo, M., Giuffrida, A., Stella, N.: Endogenous cannabinoid signaling. Neurobiol. Dis., 1998, 5, s. 462-473.
19. Maccarrone, M., van der Stelt, M., Rossi, A. et al.: Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem., 1998, 273, s. 32332-32339.
20. Chen, P., Hu, S., Harmon, S. D. et al.: Metabolism of anandamide in cerebral microvascular endothelial cells. Prostaglandins Other. Lipid. Mediat., 2004, 73, s. 59-72.
21. Ishioka, N., Bukoski, R. D.: A role for N-arachidonylethanolamine (anandamide) as the mediator of sensory nerve-dependent 2+induced relaxation. J. Pharmacol. Exp. Ther., 1999, 289, s. 245-250.
22. Ortega-Gutierrez, S., Hawkins, E. G., Viso, A. et al.: Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry, 2004, 43, s. 8184-8190.
23. Karlsson, M., Pahlsson, C., Fowler, C. J.: Reversible, temperature-dependent, and AM404-inhibitable adsorption of anandamide to cell culture wells as a confounding factor in release experiments. Eur. J. Pharm. Sci., 2004, 22, s. 181-189.
24. Bisogno, T., Katayama, K., Melck, D. et al.: Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells-implications for cell proliferation and differentiation. Eur. J. Biochem., 1998, 254, s. 634-642.
25. Fernandez, J. R., Allison, D. B.: Rimonabant Sanofi-Synthelabo. Curr. Opin. Investig. Drugs., 2004, 5, s. 430-435.
26. Cleland, J. G., Ghosh, J., Freemantle, N. et al.: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac esynchronisation therapy in heart failure. Eur. J. Heart Fail., 2004, 6, s. 501-508.